DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
November 22, 2021 07:02 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 10, 2021 07:02 ET | Diffusion Pharmaceuticals Inc.
Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
Figure 1.
Diffusion Pharmaceuticals Issues Letter to Shareholders
September 09, 2021 07:32 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
September 08, 2021 07:32 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
August 30, 2021 07:32 ET | Diffusion Pharmaceuticals Inc.
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND  Fourth FDA Division to Clear TSC IND   CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
June 30, 2021 07:35 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients
May 10, 2021 07:50 ET | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...